The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Nanoparticle therapeutics: a personal perspective
Abstract
Nanotechnology offers many potential benefits to cancer research through passive and active targeting, increased solubility/bioavailablility, and novel therapies. However, preclinical characterization of nanoparticles is complicated by the variety of materials, their unique surface properties, reactivity, and the task of tracking the individual components of multicomponent, multifunctional nanoparticle therapeutics in in vivo studies. There are also regulatory considerations and scale‐up challenges that must be addressed. Despite these hurdles, cancer research has seen appreciable improvements in efficacy and quite a decrease in the toxicity of chemotherapeutics because of ‘nanotech’ formulations, and several engineered nanoparticle clinical trials are well underway. This article reviews some of the challenges and benefits of nanomedicine for cancer therapeutics and diagnostics. © 2009 John Wiley & Sons, Inc. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Immunological properties of engineered nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.223 · Cited by 1,823
Self-citationEffects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
PATRI, A., KUKOWSKALATALLO, J., & BAKERJR, J. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.014 · Cited by 597
Cited by
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Current hurdles to the translation of nanomedicines from bench to the clinic
Đorđević, S., Gonzalez, M. M., Conejos-Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi-Fainaro, R., Florindo, H. F., & Vicent, M. J. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01024-2 · Cited by 657
Perry, J. L., Reuter, K. G., Kai, M. P., Herlihy, K. P., Jones, S. W., Luft, J. C., Napier, M., Bear, J. E., & DeSimone, J. M. (2012) · Nano Letters · doi:10.1021/nl302638g · Cited by 606
ZnO Nanoparticles: A Promising Anticancer Agent
Bisht, G., & Rayamajhi, S. (2016) · Nanobiomedicine · doi:10.5772/63437 · Cited by 506
Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives
Hahn, M. A., Singh, A. K., Sharma, P., Brown, S. C., & Moudgil, B. M. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-4207-5 · Cited by 485
Metadata
- Authors
- McNeil, S. E.
- Venue
- WIREs Nanomedicine and Nanobiotechnology
- Publisher
- Wiley
- Published
- 2009-01-13
- Volume
- 1
- Issue
- 3
- Pages
- 264-271
- ISSN
- 1939-0041 (ISSN-L)
- 1939-5116
- OpenAlex
- W2171527597
- Cited by
- 230
- References
- 5
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanoparticle therapeutics: a personal perspective. https://app.cochat.ai/papers/10.1002/wnan.6
- The paper
- McNeil, S. E. (2009). Nanoparticle therapeutics: a personal perspective. WIREs Nanomedicine and Nanobiotechnology. https://doi.org/10.1002/wnan.6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.